In the late 1990s, a new magnetic resonance imaging (MRI) pulse sequence was developed which involved intravenous administration of gadolinium contrast. The technique, dubbed delayed contrast enhanced ...

Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people ...

A pre-clinical biopharmaceutical company dedicated to precision cardiology through targeted RNA therapeutics designed to ...

The European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online today in European Heart Journal. This is the first international guideline document to include all ...

DelveInsight's Gene Therapies for Cardiomyopathies Market Insights report includes a comprehensive understanding of current treatment practices, emerging gene therapies for cardiomyopathies, market ...

Early description of cardiomyopathies originated from severe, paradigmatic case series that described worst-case scenarios The entire range of cardiomyopathies has subsequently emerged, including mild ...

Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...

The Minerva Foundation’s Medix prize for research in clinical medicine has this year been awarded to Academy Professor Anu Wartiovaara’s research group at the University of Helsinki. The group, ...

Atrium Therapeutics Inc. has launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics.

Cardiomyopathies are diseases characterised by structural and functional abnormalities of the myocardium. There are various types and subtypes, which means that tests, treatments and patient advice ...

GlobalData’s research reveals that North America accounted for 51.7% of cardiomyopathy drug sales in the 68M in 2021 and is expected to account for 54.2% in 2031. (File) The cardiomyopathies market is ...